Literature DB >> 33000417

Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity.

Mariko Nishie1, Eiji Suzuki2,3, Masakazu Hattori4, Kosuke Kawaguch1, Tatsuki R Kataoka5, Masahiro Hirata5, Fengling Pu1, Takeshi Kotake1, Moe Tsuda1, Ayane Yamaguchi1, Tomoharu Sugie6, Masakazu Toi1.   

Abstract

Among several mechanisms for the resistance of human epidermal growth factor receptor 2-overexpressing (HER2 +) cancer cells to trastuzumab, little is known regarding the mechanism underlying the resistance to trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC). Cell death due to ADCC is caused by apoptosis of target cells induced by granzymes released from natural killer cells. Because optimal granzyme physiological activity occurs at neutral pH, we assumed that the pH of the intracellular environment influences the cytotoxic effects of granzymes. We established ADCC-resistant cells and compared them with wild-type cells in terms of the expression of intracellular pH-regulating genes. The expression of ATP6V1B1, which encodes a component of vacuolar ATPases, was downregulated in the ADCC-resistant cells. Thus, to functionally characterize ATP6V1B1, we used a CRISPR/Cas9 system to generate ATP6V1B1-knockout SKBR3 and JIMT-1 cells (both HER2 + human breast cancer cell line). The resulting cells exhibited significantly less ADCC than the control SKBR3 and JIMT-1 cells. The intracellular pH of the ATP6V1B1-knockout SKBR3 and JIMT-1 cells was significantly lower than control SKBR3 and JIMT-1cells. An analysis of granzyme dynamics during the ADCC reaction in cancer cells revealed that granzymes degraded intracellularly in the control SKBR3 and JIMT-1 cells and accumulated in ATP6V1B1-knockout cells, but were not cytotoxic. These findings suggest that decreased vacuolar ATPase activity alters the cytoplasmic pH of cancer cells to create an environment that is less suitable for granzyme bioactivity, which adversely affects the induction of apoptosis of cancer cells by NK cells.

Entities:  

Keywords:  ADCC; Breast Cancer; Granzyme; HER2; Trastuzumab; V-ATPase

Mesh:

Substances:

Year:  2020        PMID: 33000417     DOI: 10.1007/s00262-020-02732-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

Review 1.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.

Authors:  D Harari; Y Yarden
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.

Authors:  Yan Wang; Judith Hailey; Denise Williams; Yaolin Wang; Philip Lipari; Michael Malkowski; Xiaoying Wang; Lei Xie; Guanghua Li; Deba Saha; Wai Lam W Ling; Susan Cannon-Carlson; Robert Greenberg; Robert A Ramos; Robert Shields; Leonard Presta; Peter Brams; W Robert Bishop; Jonathan A Pachter
Journal:  Mol Cancer Ther       Date:  2005-08       Impact factor: 6.261

4.  p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.

Authors:  Rosana Sáez; Miguel A Molina; Elizabeth E Ramsey; Federico Rojo; Edward J Keenan; Joan Albanell; Ana Lluch; Javier García-Conde; José Baselga; Gail M Clinton
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

Authors:  Peter Nagy; Elza Friedländer; Minna Tanner; Anita I Kapanen; Kermit L Carraway; Jorma Isola; Thomas M Jovin
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

6.  Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Authors:  Florian Reim; Yvonne Dombrowski; Cathrin Ritter; Mathias Buttmann; Sebastian Häusler; Monika Ossadnik; Mathias Krockenberger; Dagmar Beier; Christoph P Beier; Johannes Dietl; Jürgen C Becker; Arnd Hönig; Jörg Wischhusen
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

7.  Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Authors:  Maurizio Scaltriti; Federico Rojo; Alberto Ocaña; Judit Anido; Marta Guzman; Javier Cortes; Serena Di Cosimo; Xavier Matias-Guiu; Santiago Ramon y Cajal; Joaquin Arribas; José Baselga
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

8.  Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.

Authors:  Lise Roca; Véronique Diéras; Henri Roché; Emmanuelle Lappartient; Pierre Kerbrat; Laurent Cany; Stéphanie Chieze; Jean-Luc Canon; Marc Spielmann; Frédérique Penault-Llorca; Anne-Laure Martin; Christel Mesleard; Jérôme Lemonnier; Patricia de Cremoux
Journal:  Breast Cancer Res Treat       Date:  2013-06-19       Impact factor: 4.872

9.  Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells.

Authors:  Jerome Thiery; Dennis Keefe; Steeve Boulant; Emmanuel Boucrot; Michael Walch; Denis Martinvalet; Ing Swie Goping; R Chris Bleackley; Tomas Kirchhausen; Judy Lieberman
Journal:  Nat Immunol       Date:  2011-06-19       Impact factor: 25.606

10.  Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.

Authors:  S Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; C A Hudis; L Norton; D B Solit; J Arribas; J Baselga; N Rosen
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

View more
  2 in total

1.  X-box binding protein 1 (XBP1): a potential role in chemotherapy response, clinical pathologic features, non-inflamed tumour microenvironment for breast cancer.

Authors:  Zhipeng Zhu; Hongliang Zhan; Anran Sun; Heqing Huang; Baisheng Chen; Fuxing Zhang
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

Review 2.  The V-ATPases in cancer and cell death.

Authors:  Fangquan Chen; Rui Kang; Jiao Liu; Daolin Tang
Journal:  Cancer Gene Ther       Date:  2022-05-03       Impact factor: 5.854

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.